These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3064779)

  • 1. Treatment costs of adjuvant cytotoxic therapy in premenopausal breast cancer patients.
    Løber J; Søgaard J; Mouridsen HT; Jørgensen J
    Acta Oncol; 1988; 27(6A):767-71. PubMed ID: 3064779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.
    Dombernowsky P; Brincker H; Hansen M; Mouridsen HT; Overgaard M; Panduro J; Rose C; Axelsson CK; Andersen J; Andersen KW
    Acta Oncol; 1988; 27(6A):691-7. PubMed ID: 3064774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer.
    Brincker H; Mouridsen HT; Andersen KW
    Breast Cancer Res Treat; 1983; 3(1):91-5. PubMed ID: 6347278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
    Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
    Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
    Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Andersson M; Kamby C; Knoop AS;
    Cancer; 2010 May; 116(9):2081-9. PubMed ID: 20186830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B; Mouridsen HT; Jensen MB
    Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmastectomy irradiation in high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group trials.
    Overgaard M; Christensen JJ; Johansen H; Nybo-Rasmussen A; Brincker H; van der Kooy P; Frederiksen PL; Laursen F; Panduro J; Sørensen NE
    Acta Oncol; 1988; 27(6A):707-14. PubMed ID: 3064776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
    Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
    Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
    Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
    Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
    Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
    J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy (CMF) for stage III breast cancer: a randomized trial.
    Derman DP; Browde S; Kessel IL; De Moor NG; Lange M; Dansey R; Seymour L; Bezwoda WR
    Int J Radiat Oncol Biol Phys; 1989 Aug; 17(2):257-61. PubMed ID: 2666363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast cancer].
    Noël G; Mazeron JJ
    Cancer Radiother; 2001 Apr; 5(2):206-7. PubMed ID: 11355592
    [No Abstract]   [Full Text] [Related]  

  • 17. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
    Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
    Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
    J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer.
    Lamb D; Atkinson C; Joseph D; O'Brien P; Ackland S; Bonaventura A; Dady P; Hamilton C; Spry N; Stewart J; Denham J
    Australas Radiol; 1999 May; 43(2):220-6. PubMed ID: 10901906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.
    Montemurro F; Gatti M; Redana S; Jacomuzzi ME; Nanni D; Durando A; Popolo M; Ponzone R; Rossi A; Albieri V; Valabrega G; Sismondi P; Gabriele P; Aglietta M
    J Chemother; 2006 Feb; 18(1):90-7. PubMed ID: 16572899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.